Cal Strode
Cal Strode is a communications consultant specializing in health, science, and innovation, with experience in these sectors across the UK, Canada, and U.S. Previously, he was the Manager, Communications at CCRM. Before that, he worked with the UK’s National Institute for Health Research (NIHR) Applied Research Collaboration North West Coast (ARC NWC) and UK Research & Innovation’s (UKRI) 3DBioNet network. He also has five years of public health communications experience, delivering national campaigns with measurable impact in the fields of mental and sexual health. With an interest in how effective communications can catalyze change, his undergraduate thesis on the topic won the European Public Relations Education and Research Association (EUPRERA) award, which led to him presenting his findings at EUPRERA’s congress in Brussels. Outside of work, he enjoys surfing and open-water swimming. Follow him on X @CalStrode.
Posts by: Cal
ARM Sector Snapshot: Gene editing takes centre stage and 2023 approvals near
Regular readers of Alliance for Regenerative Medicine (ARM) sector reports may have noticed that the organization is taking a new approach to sharing insights on the cell and gene therapy sector. In April, ARM launched a new format for distilling key data and trend insights. Let’s delve into the key highlights from April’s inaugural Sector […]
Counting iPSheep: Challenges keeping CGT leaders up at night
The first Science Huddle panel discussion of 2023, Cell & Gene Therapy: Maximizing Commercialization, delved into challenges keeping leaders in the cell and gene therapy (CGT) commercialization space up at night. Moderating the event was Dr. Christian K. Schneider, Head of Biopharma Excellence, who has held leadership roles with both Danish and UK regulatory agencies, […]
A new kind of influencer: Dr. Peter Zandstra on engineering cell fate decisions
Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are developing technologies set to transform the lives of patients) and he’s the founding Director of the University of British […]
Eye on AI: Key takeaways from POLITICO’s sit-down with Peter Marks
In a wide-ranging interview with POLITICO reporter Robert King at the Next Generation of Health Care Therapies event, Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), discussed cell and gene therapies (CGT) and the role regulatory streamlining and Artificial Intelligence (AI) are both likely […]